Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal by Rojas-Rivera, Jorge Enrique et al.
E D I T O R I A L C O M M E N T
Treatment of idiopathic membranous nephropathy in
adults: KDIGO 2012, cyclophosphamide and
cyclosporine A are out, rituximab is the new normal
Jorge Enrique Rojas-Rivera1,2,3, Sol Carriazo1,2,3 and Alberto Ortiz1,2,3
1IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid, Madrid, Spain,
2Fundacion Renal I~nigo Alvarez de Toledo-IRSIN, Madrid, Spain and 3REDINREN, Madrid, Spain
Correspondence to: Alberto Ortiz; E-mail: aortiz@fjd.es
ABSTRACT
The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerulonephritis shed light
on the complex world of glomerulonephritis therapy. However, they may no longer apply to idiopathic membranous
nephropathy, as recently concluded by the KDIGO 2019 Working Group. This is due to the discovery of autoantibodies such
as anti-phospholipase A2 receptor (anti-PLA2R) that allow disease monitoring as well as to results from recent clinical
trials, comparative cohort studies and meta-analyses. Perhaps the most disruptive of them is the Membranous
Nephropathy Trial of Rituximab (MENTOR) trial comparing rituximab with cyclosporine A, which supports the superiority of
rituximab in efficacy and safety. Furthermore, rituximab results compared favourably with the short-term results of
classical clinical trials that supported the KDIGO 2012 recommendation of immunosuppressive cyclophosphamide-based
regimens as first choice for active treatment of idiopathic membranous nephropathy. Thus, the KDIGO recommendations
for cyclophosphamide-based regimens or calcineurin inhibitors as the first line of active treatment regimens for idiopathic
membranous nephropathy with nephrotic syndrome may no longer apply. By contrast, rituximab-based regimens or other
B-cell-targeted therapies appear to represent the present and future of membranous nephropathy therapy.
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INTRODUCTION
Idiopathic membranous nephropathy is the most common
cause of nephrotic syndrome in white adults [1]. The autoanti-
body responsible for the characteristic immune deposits has
been identified as anti-phospholipase A2 receptor (anti-PLA2R)
in >70% of cases. Less frequently, the disease is caused by anti-
thrombospondin type-1 domain-containing 7A (anti-THSD7A)
(7%) or as yet unidentified antibodies [2]. Despite advances in
understanding the pathogenesis, therapy remains controver-
sial. As it is a rare disease, clinical trials are usually small and
with a short follow-up. Additionally, the natural course is very
variable, ranging from spontaneous remission to severe ne-
phrotic syndrome progressing to end-stage kidney disease
(ESKD). In July 2019, the results of the Membranous
Nephropathy Trial of Rituximab (MENTOR) trial comparing rit-
uximab versus cyclosporine A were published [3]. These results
support the superiority of rituximab in efficacy for achieving re-
mission of proteinuria and in safety. We believe this will bring a
major paradigm shift in how the disease is treated, rendering
the Kidney Disease: Improving Global Outcomes (KDIGO) 2012
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Editorial Comment
recommendations obsolete [4]. We now comment on the poten-
tial impact of MENTOR on routine clinical management of idio-
pathic membranous nephropathy and try to anticipate future
changes in international guidelines.
WHAT DID KDIGO 2012 SAY ABOUT THERAPY
OF IDIOPATHIC MEMBRANOUS NEPHROPATHY
IN ADULTS?
The KDIGO 2012 recommended that initial therapy with immu-
nosuppressants be started only in patients with nephrotic syn-
drome AND when at least one of the following conditions is met
[4]:
(i) Urinary protein excretion persistently exceeds 4 g/day
AND remains at >50% of the baseline value, AND does
not show progressive decline during antihypertensive
and antiproteinuric therapy during an observation period
of at least 6 months.
OR
(ii) Presence of severe, disabling or life-threatening symptoms
related to the nephrotic syndrome.
OR
(iii) Serum creatinine (sCr) has risen by 30% within 6–12
months from the time of diagnosis but the estimated glo-
merular filtration rate (eGFR) is not lower than 25–30 mL/
min/1.73 m2 AND this change is not explained by super-
imposed complications.
Thus, immunosuppressants may be initiated immediately if
there is severely symptomatic nephrotic syndrome; otherwise,
a waiting period of 6–12 months is suggested, and immunosup-
pressants are only initiated if there is persistently very high pro-
teinuria despite antiproteinuric therapy for 6 months or sCr
increases 30% (e.g. from 0.6 to 0.8 mg/dL or from 1.8 to 2.4 mg/
dL, with 2.4 mg/dL being equivalent to 30 and 23 mL/min/1.73
m2 in a 50-year-old male and female, respectively) spontane-
ously in these 6–12 months (Figure 1A). Antiproteinuric therapy
implies renin–angiotensin system (RAS) blockade. However,
KDIGO 2012 recommended that immunosuppressive therapy
should not be used in patients with an sCr persistently >3.5 mg/
dL (equivalent to eGFR 19 mL/min/1.73 m2 or 14 mL/min/1.73 m2
in a 50-year-old white male and female, respectively) or an
eGFR <30 mL/min/1.73 m2 AND reduced kidney size on ultra-
sound (e.g. <8 cm in length) OR those with concomitant severe
or potentially life-threatening infections.
The initial recommended therapy was a 6-month course of
alternating monthly cycles of oral and intravenous (i.v.) cortico-
steroids, and oral alkylating agents, and further suggested using
cyclophosphamide rather than chlorambucil as initial alkylat-
ing agent. Then KDIGO 2012 recommended that patients be
managed conservatively for at least 6 months following the
completion of this regimen before being considered a treatment
failure if there was no remission, unless kidney function was
deteriorating or severe, disabling or potentially life-threatening
symptoms related to the nephrotic syndrome were present.
There was a suggestion to adjust the dose of cyclophosphamide
or chlorambucil according to the patient’s age and eGFR. It fur-
ther suggested that continuous daily (non-cyclical) use of oral
alkylating agents may also be effective but can be associated
with greater risk of toxicity, particularly when administered for
>6 months.
As alternative regimens for initial therapy, KDIGO recom-
mended calcineurin inhibitors (CNIs) cyclosporine A or tacroli-
mus for at least 6 months in patients who choose not to receive
the cyclical corticosteroid/alkylating agent regimen or who have
contraindications to this regimen. It further suggested that CNIs
be discontinued in patients who do not achieve complete or
partial remission after 6 months of treatment. It further sug-
gested that the dosage of CNI be reduced at intervals of 4–8
weeks to a level of 50% of the starting dosage, provided that re-
mission is maintained, and no treatment-limiting CNI-related
nephrotoxicity occurs for at least 12 months.
For the treatment of idiopathic membranous nephropathy
resistant to recommended initial therapy, KDIGO 2012 sug-
gested using the alternative regimen. It further suggested that
relapses of nephrotic syndrome be treated by reinstitution of
the same therapy that resulted in initial remission. If a 6-month
cyclical corticosteroid/alkylating agent regimen was used for
initial therapy, the regimen was suggested to be repeated only
once for treatment for a relapse.
Thus, KDIGO 2012 does not consider rituximab, despite suc-
cessful experiences reported since 2002, as these were not part
of formal clinical trials [5], but considers cyclophosphamide/
corticosteroids or CNIs as potential first-line, alternative
regimens.
WHATWAS THE EVIDENCE TO RECOMMEND
ALKYLATING AGENTS AND TO SUGGEST
CYCLOPHOSPHAMIDE AS THE PREFERRED
IMMUNE-SUPPRESSIVE AGENT?
The KDIGO 2012 provides a table summary of the evidence sup-
porting the recommendation [4]. Since MENTOR conclusively
demonstrated the superiority of rituximab over cyclosporine A,
let us review the evidence supporting the recommendation of
cyclophosphamide/corticosteroids. A meta-analysis mixing dif-
ferent alkylating regimens, randomized controlled trials (RCTs)
testing chlorambucil and one RCT using cyclophosphamide are
cited as evidence for recommending alkylating agents and for
suggesting the use of cyclophosphamide. From our point of
view, different drugs with different dosing regimens, different
safety profile and very different follow-up periods should not be
mixed in a meta-analysis, even if both are alkylating agents.
This was useful in the face of scarce evidence available consist-
ing of small trials with short follow-up, but is no longer admissi-
ble when other drugs have provided solid evidence of efficacy in
well-run RCTs with an active comparator. Thus, we focus on the
individual evidence supporting the use of cyclophosphamide/
corticosteroids.
The open-label randomized study cited by KDIGO 2012 to
support cyclophosphamide use compared the experimental reg-
imen (methylprednisolone i.v. 1 g/day for three consecutive
days followed by oral prednisolone 0.5 mg/kg/day for 27 days in
the first, third and fifth months and oral cyclophosphamide at
2 mg/kg/day in the second, fourth and sixth months, with an ap-
proximate total dose of 13.5 g) versus supportive therapy (die-
tary sodium restriction, diuretics and antihypertensive agents
excluding RAS blockade) in adults with nephrotic syndrome
(proteinuria >3.5 g/day) caused by biopsy-proven idiopathic
membranous nephropathy of 6-month duration, and patients
were followed for at least 10 years [6] (Table 1). The article states
that ‘study endpoints were doubling of sCr, development of
ESRD, or mortality’, but it does not indicate which were primary
and which were secondary endpoints. The Results section
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suggests that this may be a combined endpoint. Although it is
stated that the analysis was performed with an intention-to-
treat (ITT) basis, patients who were lost in follow-up from 18 to
48 months were excluded from analysis and no baseline or even
short-term remission results were reported. One hundred and
four patients were recruited from 1993 to 1995: 53 control and 51
active therapy, but 11 were lost in follow-up and were not ana-
lysed (11% of the initial sample). Thus, the analysis cannot be
considered either ITT or modified ITT. The power of the study
and sample size calculations were not specified. Whether there
was a pre-specified follow-up is also unclear from the report.
The cohort was younger (mean age 37–38 years) than European
or American cohorts. There was no apparent exclusion criterion
based on eGFR. Initial remission (<2 g/day or <50% of baseline,
along with normal sCr) was achieved within 1 year of randomi-
zation in 5/53 (9%) and 15/51 (29%) of ITT patients in control and
experimental groups, respectively, and ever remission in 16/53
(30%) and 34/51 (67%), respectively. Of these, 5/53 (9%) and 15/51
(29%) were complete remissions at 10 years. Thus, overall, cy-
clophosphamide/steroids achieved a complete remission in an
additional 20% of patients, on top of spontaneous complete
remissions observed with supportive therapy that initially ex-
cluded RAS blockade (Figure 2A and B; Supplementary data,
Figure S1). Complete remissions on active therapy were ob-
served in <10% of patients at 12 months. The proportion of
patients on complete remission continued to increase up to 40
months and then stabilized (Figure 2C and D). Relapses occurred
in 4/16 (25%) and 8/34 (24%) for control and cyclophosphamide/
steroids patients, respectively, 5.46 6.2 months after the first
remission in those on cyclophosphamide/steroids (Figure 2E).
These patients were treated with addition of RAS blockade. A
total of 13/53 (25%) supportive therapy patients and 30/51 (59%)
cyclophosphamide/steroids patients were in remission until the
time of final follow-up. However, these and safety data were
confounded by prescription of immunosuppressive regimen 24
months after randomization in 15/53 (28%) supportive therapy
patients. Treatment of the control cohort would not have been
considered standard today since RAS blockade was prohibited
initially and only prescribed to 17/53 (32%) at 2 years and this in-
creased to 32/53 (60%) at 10 years.
The trial also reported long-term outcomes. For the first
7 years, the incidence of renal replacement therapy was low
and there were no differences between the groups (<5% in both
groups). However, the 10-year dialysis-free survival was 65%
and 89% of the analysed patients in the control and treatment
groups, respectively (P¼ 0.016). The combined endpoint was sig-
nificantly more frequent in the control analysed patients and
started to diverge at 6 years. At 20 months of follow-up, eGFR
was similar in both groups but then diverged. At 1 year, protein-
uria in the analysed patients of the intervention group was
>3 g/day. Timing considerations are important when interpret-
ing results from other therapeutic regimens that lack the long-
term follow-up.
It is also worth mentioning a prior Ponticelli et al. study [7] of
cyclophosphamide/steroids with primary endpoint not speci-
fied and a shorter follow-up, without clarification of whether
there was a pre-specified follow-up, in which the comparator
was chlorambucil/steroids and no ITT data were presented.
Excellent overall remission results were observed at 1 year and
they continued to improve up to 5 years, but these results were
at odds with other cyclophosphamide/steroids studies and the
difference may likely be traced back to the inclusion of patients
FIGURE 1: The KDIGO 2012 recommendations for treatment of idiopathic membranous nephropathy in adults and the 2019 MENTOR-based shift of paradigm. (A) The KDIGO
2012 recommendations for treatment of idiopathic membranous nephropathy [4]. Two alternative immunosuppressive regimens are proposed if there is no initial response to
antiproteinuric therapy for 6 months. Immunosuppression may be started earlier if nephrotic syndrome is very symptomatic or eGFR decreases. Cyclophosphamide/steroids
are preferable as the first choice over CNIs. Cyclophosphamide/steroids are maintained for 6 months but are not considered to have failed until Month 12. If at this point in
time there is failure, CNIs are the alternative. CNI therapy is considered a failure if no remission is achieved within 6 months, at which point, cyclophosphamide/steroids are
proposed as an alternative. If remission is achieved, CNI should be maintained for at least 12 months. Given the high recurrence rate upon withdrawal, CNI dose is decreased
over time. (B) The 2019 MENTOR-based change of paradigm for treatment of idiopathic membranous nephropathy [3]. Rituximab is administered as two consecutive 1 g doses
separated by 2 weeks that may be repeated at 6 months when there has been no response to antiproteinuric therapy for 3 months. This regimen was shown to be superior in
efficacy achieving remission and safety, maintaining better renal function than cyclosporine A, a CNI. (C) Alternative proposal for rituximab-based idiopathic membranous ne-
phropathy therapy. Based on the lag-time to complete remission since initial rituximab dosing and the safety profile of rituximab, this proposal is aimed at minimizing com-
plications from nephrotic syndrome. The use of a single dose of rituximab may limit the economic impact of rituximab, and the earlier start of rituximab may result in a
shorter nephrotic syndrome exposure. RASi, renin–angiotensin system inhibitors; IIS-FJD, Instituto Investigacio´n Sanitaria Fundacio´n Jime´nez Dı´az.
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just after diagnosis in Ponticelli et al. study [7] without a prior
expectant attitude towards spontaneous remission (Table 1).
Indeed, the rate of complete remission was lower and in line
with Jha et al. [6] (Figure 2C and D). The use of RAS blockade was
discouraged and the relapse rate of 25% for cyclophosphamide/
steroids was in line with the study by Jha et al. [6, 7] (Figure 2E).
As a summary of the evidence supporting the prescription of
cyclophosphamide/steroids, these RCTs would be hardly admissi-
ble as evidence under current standards, given the outdated
methodology used, without clarification of pre-specified end-
points or follow-up time; the suboptimal symptomatic therapy,
which discouraged or prohibited RAS blockade; and other pecu-
liarities of the studies, such as the younger than usual population
or the lack of an expectant, symptomatic therapy period before
initiation of immunosuppression. In any case, the short-term in-
formation gathered from these cyclophosphamide/steroids stud-
ies can be summarized as follows: induction of complete
remission in 20–25% of patients at 24 months, a peak complete
remission of 30–35% in months 40–60 of follow-up (for the study
that had a control comparator, this represents 20% above the con-
trol group) and a relapse rate of 25% (Table 1; Figure 2A–E).
WHAT DO RECENT META-ANALYSES SHOW?
In a 2017 network meta-analysis of RCTs (thus excluding rituxi-
mab), cyclophosphamide, cyclosporine A or tacrolimus
Table 1. Patient characteristics and results of three major randomized clinical trials in primary membranous nephropathy
Ponticelli et al. [7] Jha et al. [6] MENTOR, Fervenza et al. [3]
Requirement for pre-RCT
follow-up
None 6 months 3 months of RAS blockade









Dietary sodium restriction, diuretics
and antihypertensive agents. RAS
blockade excluded
Cyclosporine A
RAS blockade Discouraged Prohibited Required
Primary endpoint Unclear Unclear. Endpoints included doubling
of sCr, development of ESRD or pa-
tient death
Composite of complete or partial
remission at 24 months
Pre-specified follow-up Not reported Unclear.
Patients were followed for 10
years, but unclear whether this was
pre-specified. Totally, 28% of control
patients eventually received the test
drug
24 months
Duration of test drug therapy 6 months 6 months 2 weeks, could be repeated at
6 months
Follow-up (years) 1 10 2
N on experimental regimen 45 51a 65
Age (years) 48 37612 52613
Upper age limit (years) 65 None 80
Baseline eGFR (mL/min/1.73 m2) 76b 84622 85630 (Ccr)
eGFR inclusion criterion (mL/min/
1.73 m2)
42c No data 40
Baseline proteinuria (g/24 h) 6.8 6 3.5 5.962.2 8.9 (6.7–12.9)
Proteinuria inclusion criterion
(g/24 h)
>3.5 >3.5 without RAS blockade >5.0 on RAS blockade
Remission at 1 year, n/N (%) 40/45 (89) 15/51 (29) 39/65 (60)d
Complete remission, n/N (%) 16/45 (35.5), peak at
60 months
15/51 (29) peak at 40–45 months 23/65 (35). End of follow-up at
24 months
Complete remission at 24 months,
n/N (%)
20%e 25%e 23/65 (35%)
Relapses, n/N (%) 10/40 (25) 8/34 (24) within 566 months of first
remission
2/39 (5) at 24 months
Definitions
Partial remission 0.2–2 g/day 0.2–2 g/day or <50% of baseline Decrease 50% from baseline plus
final proteinuria 0.3–3.5 g/day
Complete remission, definition <0.2 g/day <0.2 g/day <0.3 g/day
Key RCTs defining how membranous nephropathy is treated have been published in the past 20 years, with approximately one-decade separation between them.
Baseline data and outcome data are shown for the intervention group. Baseline proteinuria presented as mean 6 SD or median (interquartile range).
aFifty-one randomized to test therapy, but four lost to follow-up and no baseline data provided for these four patients.
bEstimated by applying the CKD-EPI equation to mean sCr adjusted by age and sex distribution of participants.
cEstimated by applying the CKD-EPI equation to the cut-off sCr of 1.7 mg/dL adjusted by age and sex distribution of participants.
dValues at 24 months (primary endpoint) were the same.
eEstimated from figures in the article.
Ccr, creatinine clearance; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; ESRD, end-stage renal disease.
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significantly increased the rate of complete or partial remis-
sions as compared with non-immunosuppressive treatment,
but there were no significant differences in the probability of
remission between cyclosporine A and cyclophosphamide,
while drug withdrawal was more likely with cyclophosphamide
than with cyclosporine A or tacrolimus [9]. Compared with
non-immunosuppressive treatment, of these drugs only cyclo-
phosphamide significantly reduced the risk of a composite
outcome of mortality or ESKD [odds ratio ¼ 0.31, 95% confidence
interval 0.12–0.81], but there were no significant differences
between cyclophosphamide and CNIs. This result may have
been biased by the lack of long-term studies with CNIs that had
a follow-up of 12–18 months, which limits the ability to test im-
pact on these long-term outcomes (differences in mortality or
ESKD versus antihypertensive therapy were not observed for
cyclophosphamide-based regimens in the first 6–7 years of
follow-up) [6].
WHAT DID KDIGO 2019 SAY?
The recent report of the KDIGO controversies conference on





FIGURE 2: Complete remissions in key randomized clinical trials of immunosuppressive therapy in idiopathic membranous nephropathy. (A) The percentage of com-
plete emissions is shown and the time point at which these were assessed is indicated. The percentage of remissions observed in the comparator group has been sub-
tracted from the percentage in the intervention group. In Jha et al. [6], RASi were allowed only after 12 months but were only prescribed in up to 60% of patients.
(B) Percentage of complete remissions over comparator group versus time of follow-up at which they were assessed. In the Jha et al. study [6], complete remission con-
tinued to occur in the intervention group up to Month 45 and in the control group up to Month 60. Thus, the same graph as in (B) but assigning a 60-month follow-up to
this study is shown in Supplementary data, Figure S1. (C) Time course of complete remissions. Percentage of complete remissions in the intervention group without
subtracting control group complete remissions. ITT analysis. No remissions were noted in MENTOR at 6 months or in GEMRITUX. Please note that maximum follow-up
was 24 months in MENTOR and upper quartile follow-up was 23 months in GEMRITUX, so data are incomplete regarding later time points. Time-course graphs for
Ponticelli et al. [7] and Jha et al. [6] were presented in their manuscripts and indicated that some complete remissions had occurred by 6 months. Complete remissions
appear to have a lag period of 6 months for rituximab, but then they increase faster than for cyclophosphamide/steroids. The timing of complete remission plateau
under rituximab is unclear from these data. (D) Complete remissions at 24 months, without subtracting control group complete remissions. GEMRITUX data are not
presented, since the upper quartile follow-up was 23 months. (E) Relapse rate. GEMRITUX data are not presented, since the upper quartile follow-up was 23 months.
Rituximab is shown in blue and cyclophosphamide/steroids in red. Jha et al. [6] data were presented on an ITT basis, except for (D), in which they were estimated from
a graph, and thus represent patients with available data. The definition of complete remission and percentage of complete remissions in the comparator group were as
follows: Ponticelli et al. and Jha et al.: proteinuria <0.2 g/day, complete remissions in comparator group in Jha et al. 5/53 (9%), in Ponticelli et al. comparator was chloram-
bucil/steroids, and thus the Ponticelli et al. data are not used when assessing complete remission minus control complete remissions; MENTOR: proteinuria <0.3 g/day,
complete remissions in comparator group none; GEMRITUX: proteinuria <0.5 g/day, complete remissions in comparator group 1/38 (3%) [3, 6–8]. RASis, renin–angioten-
sin system inhibitors.
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that nearly all of the KDIGO 2012 membranous nephropathy
recommendations should be revisited based on the discovery of
podocyte antigen targets of circulating antibodies and on recent
clinical studies and trials [4, 10]. We agree with this assessment.
WHAT DID THE MENTOR TRIAL OF RITUXIMAB
VERSUS CYCLOSPORINE A SHOW?
In July 2019, the MENTOR trial of rituximab versus cyclosporine
A for idiopathic membranous nephropathy in adults was pub-
lished [3]. MENTOR randomized 130 membranous nephropathy
patients with proteinuria 5 g/day despite at least 3 months of
RAS blockade, and an eGFR 40 mL/min/1.73 m2 to receive oral
cyclosporine A for 12 months or two rituximab infusions,
1000 mg each, administered 14 days apart and repeated at
6 months in case of partial response. The primary outcome was
a composite of complete or partial remission of proteinuria at
24 months (Table 1). At 24 months, 39/65 patients (60%) in the
rituximab group and 13/65 (20%) in the cyclosporine A group
had a complete or partial remission (P< 0.001). Additionally, at
24 months, 23 rituximab patients (35%) and no cyclosporine A
patient had a complete remission (Figure 2A–D). Among
patients who achieved remission, the decline in anti-PLA2R
antibodies was faster and larger in the rituximab group, sug-
gesting that rituximab-induced immunological remission pre-
cedes kidney remission. Serious adverse events tended to be
less common with rituximab [11/65 (17%) versus 20/65 (31%);
P¼ 0.06], which better preserved kidney function.
While MENTOR did not directly compare rituximab with cy-
clophosphamide, the results were similar to or better than his-
torical RCTs that formed the basis of the KDIGO 2012
recommendation of alkylating agents and preferably cyclophos-
phamide in association with steroids as the first line of therapy
for idiopathic membranous nephropathy (Figure 2A–E) [6, 7].
Thus, although the onset of complete remissions induced by rit-
uximab may have a lag time of at least 6 months from the start
of therapy (Figure 2C), both the overall rate of complete remis-
sions at 24 months and the excess rate of complete remissions
over controls were higher for rituximab than for key prior cyclo-
phosphamide/steroids trials and the relapse rate on rituximab
at 5% was well below that reported previously for cyclophos-
phamide/steroid studies (Table 1; Figure 2A–E). However, the
different definitions of remission used complicate the interpre-
tation of these data. Although we lack long-term follow-up data
FIGURE 3: Pathogenesis of membranous nephropathy and mechanism of action of rituximab, CNIs and cyclophosphamide: working hypothesis to explain the timing
of response and different clinical impact. Idiopathic membranous nephropathy is an autoimmune disease caused by autoantibodies that bind to the podocyte cell sur-
face antigen PLA2R, leading to podocyte injury and sub-epithelial immune complex deposits that may take months to clear after total cessation of antibody production.
B cells may already produce immunoglobulin G (IgG), but the bulk of it is produced by more mature plasma cells, which usually have a half-life of a few weeks to
months. However, a few plasma cells are long-lived and continue to produce antigen-specific IgG. Regulatory T cells (Tregs) prevent the emergence of these long-lived
plasma cells and suppress activated B cells [11]. Plasma cells are not rituximab targets. Rituximab binds to and kills CD20-expressing B cells. B-cell death may involve
different molecular mechanisms but complement-mediated cell death appears to be important since cell culture studies have identified specific complement regula-
tory protein that confers resistance to rituximab-induced B-cell death [12]. Additionally, membranous nephropathy patients responding to rituximab display an upre-
gulation of Tregs, which is not present in patients not responding or in controls [13]. Cyclophosphamide selectively targets T, B and other lymphocytes over other cell
types, as they have the molecular machinery to activate cyclophosphamide through a b-elimination reaction [14]. However, it has off-target effects in multiple other
cell types, and the impact of cyclophosphamide on Tregs is dose and time sensitive [15]. This variable impact of cyclophosphamide on Tregs, in which lower doses may
actually inhibit Tregs [16], may underlie the relatively high relapse rate as opposed to rituximab. Finally, cyclosporine A is a T cell immunosuppressive drug that addi-
tionally has glomerular haemodynamic effects, decreasing GFR and proteinuria, as well as an actin cytoskeleton-stabilizing effect on podocytes that may also contrib-
ute to decrease proteinuria [17]. Frequent need for continuous administration of the drug to maintain remission points is an important contribution of direct impact
on glomerular haemodynamics and podocytes, which require continuous presence of the drug. From this point of view, rituximab and cyclophosphamide may be con-
sidered disease-modifying drugs, but the use of this term for cyclosporine A may be disputed.
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for rituximab, both the higher percentage of complete remis-
sions and the lower relapse rate bode well for long-term
outcomes.
WHATWERE THE SHORTCOMINGS OF THE
GEMRITUX TRIAL OF RITUXIMAB VERSUS
CONVENTIONAL ANTIPROTEINURIC
TREATMENT ALONE?
GEMRITUX was a prior, recent and smaller (n¼ 75) trial with
shorter follow-up (6 months for the primary endpoint) of rituxi-
mab versus conventional antiproteinuric treatment [8]. All
patients received conventional antiproteinuric treatment and
rituximab was administered in two 375-mg/m2 i.v. infusions 7
days apart to 37 patients. From an evidence-based medicine
point of view, GEMRITUX was disappointing since it missed the
primary endpoint: at Month 6, 13 (35%) patients on rituximab
and 8 (21%) patients on conventional antiproteinuric treatment
achieved a complete or partial remission (P¼ 0.21). Thus, rituxi-
mab appeared no different than antiproteinuric therapy alone.
However, the design of this study was severely flawed and not
adjusted to the current understanding of the pathogenesis of
membranous nephropathy and the mechanism of action of rit-
uximab (Figure 3) [18]. Thus, rituximab reduces the number of B
cells and this results in a progressive decrease in circulating an-
tibody titers, the same antibodies that are deposited in the sub-
epithelial space. However, even if antibody deposition ceases
suddenly, sub-epithelial deposits are long-lived, so a slow and
progressive decrease in deposits and proteinuria is expected
[19]. Thus, the 6-month time point was unrealistic for therapeu-
tic success as further supported by zero complete remissions
observed in MENTOR at this time point (Figure 4A). Fortunately,
FIGURE 4: Rituximab dosing and remissions. (A) Different initial dosing regimens used by GEMRITUX (two 375-mg/m2 infusions separated by 1 week, total dose 1.45 g)
and MENTOR (two 1-g infusions separated by 2 weeks, total dose 2 g) resulted in similar complete remissions and overall remissions from 6 to 24 months of follow-
up. In MENTOR, dosing could be repeated after 6 months. There were no statistically significant differences. Both populations had similar age and GFR, but proteinuria
was numerically higher in GEMRITUX [3, 20]. Graphs were constructed using only 6- and 24-month time points. For GEMRITUX, data used were from anti-PLA2R-posi-
tive patients from Seitz-Polski et al. [20], since they provide complete remission data at 6 months. (B) Impact of single-dose rituximab: clinical course. A 56-year-old nor-
motensive woman was diagnosed with nephrotic syndrome with preserved eGFR (103 mL/min/1.73 m2) because of primary membranous nephropathy. RAS blockade
[angiotensin-converting enzyme inhibitor (ACEi) plus spironolactone] was instituted. Initially, proteinuria decreased >50% but remained at 3500 mg/g with persisted
nephrotic syndrome. Then proteinuria again increased progressively and a single dose of rituximab 375 mg/m2 was administered. This achieved peripheral blood B-
cell depletion for >3 months and partial remission of proteinuria (nadir 525 mg/g). A second rituximab dose was administered 7 months after the first dose because of
recurrent nephrotic syndrome and resulted in peripheral blood B-cell depletion for >5 months and complete remission. In the latest follow-up, albuminuria is unde-
tectable. Overall, the patient received 1.2 g of rituximab. No adverse effects were noted. UPCR, urinary protein–creatinine ratio; UACR, urinary albumin–creatinine ratio.
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the study provided a post hoc observational follow-up of a me-
dian of 17 months from inclusion. At the end of this period, 24
of 37 (65%) rituximab and 13 of 38 (34%) conventionally treated
patients were on remission (P< 0.01). Complete remissions
were observed in 7/37 (19%) and 1/38 (3%) rituximab and anti-
proteinuric patients, respectively (P¼ 0.03). These numbers are
in line with the MENTOR data (Figures 2B and C, and 4A;
Supplementary data, Figure S1). Median times to remission
were 7.0 (interquartile range 5.5–10.5) months (n¼ 24) and 7.0
(4.0–13.0) months (n¼ 13) in the rituximab and the antiproteinu-
ric treatment groups, respectively. There were no safety differ-
ences between the two regimens, further supporting, together
with MENTOR, the safety of rituximab.
RITUXIMAB DOSE OPTIMIZATION
Both MENTOR and GEMRITUX tested a multiple dose rituximab
regimen: two consecutive 1-g doses separated by 2 weeks and
two consecutive 375-mg/m2 doses separated by 1 week, respec-
tively [3, 8] (Figure 4A). Rituximab was originally authorized to
treat lymphoma and later rheumatoid arthritis at doses of
375 mg/m2 weekly for 4 weeks (total dose of 1.73 m2 individual:
2.6 g¼ 4  0.65 g) for lymphoma and 1 g repeated 2 weeks later
(total dose 2 g) for rheumatoid arthritis. Idiopathic membranous
nephropathy regimens and RCTs just copied and adapted these
authorized and tested regimens. However, the key question is
whether the repeated initial dosing is necessary for membra-
nous nephropathy. This is a question worth asking since one of
the limitations to a more widespread use of rituximab is cost,
even though cost analysis has concluded that rituximab may be
cost-effective in the short and medium terms compared with
cyclophosphamide/steroids [21]. However, health and hospital
authorities quite often focus on the short-term and local hospi-
tal drug costs, and would put up barriers to prescribing rituxi-
mab when cyclophosphamide is cheaper. Additionally, a lower
rituximab dose may be safer, although both MENTOR and
GEMRITUX evidenced an excellent safety profile, similar to con-
ventional antiproteinuric therapy and better than cyclosporine
A. The Italian pioneers of rituximab for membranous nephropa-
thy, Ruggenenti et al. [22], have long advocated a single-dose
regimen termed as B-cell-driven rituximab treatment, in which
a second single dose is prescribed based on B-cell depletion and
proteinuria response [22]. In this regard, most membranous ne-
phropathy patients will clear circulating B cells within 24 h of a
single 375-mg/m2 rituximab dose, questioning the need for ini-
tial repetitive dosing [23, 24]. Thus, the single-dose regimen
may achieve long-term complete remission, or may be followed
by a second single dose if B cells are not depleted or following
recurrence or partial remission (Figure 4B).
Although a rituximab dose–response effect on the timing
and frequency of remission was recently suggested based on
comparison of independent studies (an observational study and
Table 2. Dose and administration regimens of rituximab for idiopathic membranous nephropathy




N for rituximab group 28 65 27a 37
Initial rituximab dose 2  1 g, 2-week interval 2  1 g, 2-week interval 2  375 mg/m2, 1-week in-
terval (total dose 1.45 g)
2  375 mg/m2, 1-week
interval
Mean age (years) 63 52 51 53
Baseline proteinuria (g/g)b 5.9 6.2 8.4 7.7
Overall remissions 6
months, n/N (%)
18/28 (64) 23/65 (35) 8/27 (30) 13/37 (35)
Complete remission 6
months, n/N (%)
5/28 (18) 0/65 (0) 0/27 (0) No data
Overall remissions
end of follow-up, n/N (%)
24/28 (86) at median
15 months
39/65 (60) at 24 months 18/27 (67) at median
24 months
24/37 (65) at median
17 months
Complete remissions
end of follow-up, n/N (%)
9/28 (32) at median
15 months
23/65 (35) at 24 months 6/27 (22) at median
24 months
No statistically significant




difference versus NICE or
MENTOR
Data from clinical trials and an observational cohort. Note that age was similar for MENTOR and GEMRITUX, GFR was similar for all groups (not shown). NICE, National
Institute for Health and Care Excellence.
aOnly anti-PLA2R-positive patients in this analysis.
bFor MENTOR, please note that in Table 2, proteinuria is expressed in g/g urinary creatinine but in Table 1 it is expressed in g/day.
Table 3. Unmet clinical needs and unanswered questions in the treatment of primary membranous nephropathy
 Relative position of rituximab versus cyclophosphamide/steroids as the first-line therapy
 Long-term rituximab outcomes: preservation of renal function and progression to ESKD
 Timing of initial rituximab indication
 Optimal dosing of rituximab
 Adjuvant therapy to accelerate remission while the disease-modifying effect of rituximab sets in
 Alternative regimens for rituximab treatment failures or improve rituximab efficacy record without compromising safety
 Role of serum anti-PLA2R antibodies specificity or titer in the individualization of immunosuppressive therapy
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the anti-PLA2R positive patients in GEMRITUX) using different
individual doses and timings between doses [20], inclusion of
the MENTOR data in the comparison argues against such a
dose–response relationship (Table 2; Figure 4A). Earlier, a higher
rate of complete and/or overall remission was reported in the
observational study using a total dose of 2 g with a 2-week inter-
val between two 1-g doses than with a total dose of 1.45 g
(375 mg/m2  2) with a 1-week interval between doses in
GEMRITUX (Table 2) [20]. The combination of higher dose and
lower epitope spreading (a measure of how many epitopes in
the PLA2R are recognized by anti-PLA2R antibodies in individual
patients) was associated with remission [20]. However, when
comparing GEMRITUX with MENTOR, which used the (higher
dose) 1  2-g protocol, these putative differences in remission
rates or timings were not apparent (Figure 4A).
ANYMORE NEWS ON THE HORIZON?
The RI-CYCLO trial, estimated to be completed by December
2019, is assessing the efficacy (primary endpoint complete re-
mission at 1 year) and safety of rituximab versus cyclophospha-
mide/steroids in 76 patients with membranous nephropathy
[25]. Another major trial, Sequential therapy with TAcrolimus
and Rituximab in primary MEmbranous Nephropathy
(STARMEN), was completed on 30 June 2019 [26]. STARMEN ran-
domized 86 patients to sequential therapy with tacrolimus for
6–9 months plus single dose of rituximab (1000 mg i.v.) or cyclo-
phosphamide/steroids. The primary endpoint was the propor-
tion of patients reaching either complete or partial remission at
24 months. Other relevant endpoints were the time to achieve
remission, number of relapses, doubling of sCr and the prognos-
tic value of anti-PLA2R antibodies. The results of this trial are to
be made public in late 2019 or 2020.
CONCLUSION
In conclusion, the MENTOR trial provided conclusive evidence
of the higher efficacy of rituximab in inducing remission and its
better safety than cyclosporine A, one of the regimens recom-
mended by KDIGO 2012. These results should be a game
changer and the future guidelines may likely recommend rituxi-
mab over CNIs.
However, unsolved issues remain (Table 3). One is the rela-
tive position of rituximab versus cyclophosphamide/steroids.
Based on the published trials with cyclophosphamide/steroids,
we believe that rituximab efficacy and safety compare favour-
ably with these regimens. Although long-term trials are missing
for rituximab, but available for cyclophosphamide/steroids, the
success in inducing complete remission with rituximab is likely
to result in improved long-term outcomes, although this
remains to be demonstrated conclusively. In this regard, the
long-term clinical trial of cyclophosphamide/steroids, on which
the KDIGO 2012 recommendations are based, would probably
not meet current management standards for proteinuric kidney
disease in the placebo arm and the current RCT design and
reporting standards [6]. Thus, this trial should be considered
outdated. The results of ongoing or recently completed trials,
RI-CYCLO and STARMEN, comparing cyclophosphamide/ste-
roids with rituximab or rituximab/tacrolimus are awaited. For
STARMEN, the complexity of the rituximab arm, which addi-
tionally includes tacrolimus, may impair its ability to represent
the impact of rituximab alone.
Another unsolved issue is the optimal dosing of rituximab.
The MENTOR regimen will likely become the standard approach
to membranous nephropathy, given that it is supported by a
clinical trial. However, regimens currently in use in membra-
nous nephropathy are derived from those used in malignancy,
and dosing could be further optimized. A lower optimized dose
would entail significant cost savings and help to extend use of
rituximab to more economically deprived healthcare systems.
Finally, treatment failure was observed in MENTOR in 26 (40%)
rituximab patients and 52 (80%) cyclosporine A patients by 24
months. Thus, the current first-line therapeutic approaches fail
to help a large number of patients. New B-cell–targeting therapies
and other promising therapeutic approaches have been reviewed
recently [18]. Additionally, an unmet clinical need is co-adjuvant
therapy that may accelerate complete remission to a >3-month
window, to be used in the time window that it takes for rituximab
or other disease-modifying regimens to induce immunological
remission and for this immunological remission to translate to
clinical remission. In this regard, given the lag time from initia-
tion of therapy to a response, the potential adverse consequences
of persistent nephrotic syndrome and the safety profile of rituxi-
mab, an argument could be made to initiate therapy as soon as
idiopathic membranous nephropathy is diagnosed (Figure 1C).
A similar argument was made to justify immediate initiation of
cyclophosphamide/steroids or chlorambucil/steroids, which
represent a less safe alternative, >20 years ago [7].
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